Cerity Partners LLC Buys 68,883 Shares of Guardant Health, Inc. (NASDAQ:GH)

Cerity Partners LLC boosted its stake in shares of Guardant Health, Inc. (NASDAQ:GH - Free Report) by 54.6% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 195,008 shares of the company's stock after purchasing an additional 68,883 shares during the period. Cerity Partners LLC owned 0.16% of Guardant Health worth $4,473,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of GH. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Guardant Health by 21.8% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,449 shares of the company's stock valued at $102,000 after acquiring an additional 796 shares during the period. JNBA Financial Advisors bought a new stake in shares of Guardant Health in the 3rd quarter valued at about $26,000. Ashton Thomas Securities LLC acquired a new stake in Guardant Health in the 3rd quarter valued at about $34,000. Quarry LP bought a new position in Guardant Health during the second quarter worth about $44,000. Finally, Green Alpha Advisors LLC increased its position in Guardant Health by 23.6% during the third quarter. Green Alpha Advisors LLC now owns 8,782 shares of the company's stock worth $201,000 after buying an additional 1,674 shares during the last quarter. 92.60% of the stock is currently owned by institutional investors.

Insider Activity at Guardant Health

In other Guardant Health news, Director Meghan V. Joyce sold 2,896 shares of the stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $29.90, for a total transaction of $86,590.40. Following the completion of the sale, the director now owns 7,648 shares of the company's stock, valued at approximately $228,675.20. This represents a 27.47 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 5.50% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

GH has been the subject of several research reports. TD Cowen raised their price target on Guardant Health from $41.00 to $42.00 and gave the company a "buy" rating in a report on Thursday, August 8th. Citigroup raised their target price on shares of Guardant Health from $40.00 to $45.00 and gave the stock a "buy" rating in a research note on Thursday, August 8th. Craig Hallum upped their price target on shares of Guardant Health from $28.00 to $37.00 and gave the company a "buy" rating in a research note on Thursday, August 8th. JPMorgan Chase & Co. raised their price objective on shares of Guardant Health from $48.00 to $50.00 and gave the stock an "overweight" rating in a research report on Thursday, November 7th. Finally, Sanford C. Bernstein decreased their target price on Guardant Health from $40.00 to $35.00 and set an "outperform" rating on the stock in a research report on Wednesday, October 30th. One analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $40.60.

Guardant Health Price Performance

NASDAQ:GH traded up $0.51 on Friday, hitting $35.61. The company had a trading volume of 815,237 shares, compared to its average volume of 2,067,785. The firm has a 50 day moving average of $25.00 and a two-hundred day moving average of $27.26. The stock has a market capitalization of $4.40 billion, a price-to-earnings ratio of -8.28 and a beta of 1.11. Guardant Health, Inc. has a 52 week low of $15.81 and a 52 week high of $37.04. The company has a current ratio of 6.22, a quick ratio of 5.85 and a debt-to-equity ratio of 16.70.

Guardant Health (NASDAQ:GH - Get Free Report) last issued its earnings results on Wednesday, November 6th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.55) by ($0.33). The firm had revenue of $191.48 million during the quarter, compared to analyst estimates of $170.49 million. Guardant Health had a negative return on equity of 1,200.44% and a negative net margin of 74.02%. Guardant Health's revenue for the quarter was up 33.9% on a year-over-year basis. During the same period in the previous year, the company earned ($0.73) EPS. On average, research analysts anticipate that Guardant Health, Inc. will post -3.38 earnings per share for the current year.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.